Grace Therapeutics Files 10-Q/A for Q3 2024
Ticker: GRCE · Form: 10-Q/A · Filed: Feb 19, 2025 · CIK: 1444192
Sentiment: neutral
Topics: 10-Q/A, amendment, pharmaceutical
TL;DR
Grace Therapeutics filed an amended 10-Q for Q3 2024, check for updates.
AI Summary
Grace Therapeutics, Inc. filed an amendment (10-Q/A) on February 19, 2025, for the quarterly period ended December 31, 2024. The company, formerly known as Acasti Pharma Inc., is incorporated in Delaware and headquartered in Princeton, New Jersey. This filing relates to their operations in the pharmaceutical preparations sector.
Why It Matters
This amended filing provides updated financial and operational information for Grace Therapeutics for the quarter ending December 31, 2024, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine amendment to a quarterly report, not indicating any immediate or significant new risks.
Key Players & Entities
- Grace Therapeutics, Inc. (company) — Registrant
- Acasti Pharma Inc. (company) — Former company name
- December 31, 2024 (date) — Quarterly period end date
- February 19, 2025 (date) — Filing date
- Princeton, New Jersey (location) — Principal executive offices
FAQ
What is the purpose of this 10-Q/A filing?
This filing is an amendment (Amendment No. 1) to the quarterly report (10-Q) for the period ended December 31, 2024.
What is the company's name and former name?
The company's current name is Grace Therapeutics, Inc., and its former name was Acasti Pharma Inc.
When was the quarterly period covered by this report?
The quarterly period ended on December 31, 2024.
On what date was this amended filing submitted?
This amended filing was submitted on February 19, 2025.
Where are Grace Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.
Filing Details
This Form 10-Q/A (Form 10-Q/A) was filed with the SEC on February 19, 2025 regarding Grace Therapeutics, Inc. (GRCE).